New ways are needed to promote synergy between industry and academia for accelerated testing of promising new drugs in the prevention of insulin resistance and type 2 diabetes, and to bring such drugs to market. Identification and validation of new targets in the inflammatory pathway with chemistry and high-throughput screening is an expensive, time-consuming line of research for academics and would be better conducted as a collaborative effort with industry. Industry is better equipped for drug development and possesses tools not usually available in academia.

Related concepts
Last update :
This website is created with material from the European Union FP7-funded DIAMAP project (concluded 2010). The content is continually being reviewed and updated as we are undertaking on-going consultation with the diabetes research community. Progress will be indicated on the road maps. You can send comments on the scientific content through the tab on the right 'make a feedback!'.
Send feedback !
Legal pages
Privacy Policy
This site uses cookies to make statistics over visiters. By using our site, you acknowledge that you have read and understand our Privacy Policy, and our Terms of Service. Your use of DIAMAP's website and services is subject to these policies and terms.